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Economic assessmenta b s t r a c t
Objective: To compare the economic impact of high-dose trivalent (HD) versus standard-dose trivalent
(SD) influenza vaccination on direct medical costs for cardio-respiratory hospitalizations in adults aged
65 years or older enrolled in the United States (US) Veteran’s Health Administration (VHA).
Methods: Leveraging a relative vaccine effectiveness study of HD versus SD over five respiratory seasons
(2010/11 through 2014/15), we collected cost data for healthcare provided to the same study population
both at VHA and through Medicare services. Our economic assessment compared the costs of vaccination
and hospital care for patients experiencing acute cardio-vascular or respiratory illness.
Results: We analyzed 3.5 million SD and 158,636 HD person-seasons. The average cost of HD and SD vac-
cination was $23.48 (95% CI: $21.29 - $25.85) and $12.21 (95% CI: $11.49 - $13.00) per recipient, respec-
tively, while the hospitalization rates for cardio-respiratory disease in HD and SD recipients were 0.114
(95% CI: 0.108–0.121) and 0.132 (95% CI: 0.132–0.133) per person-season, respectively. Attributing the
average cost per hospitalization of $11,796 (95% CI: $11,685 - $11,907) to the difference in hospitalization
rates, we estimated savings attributable to HD to be $202 (95% CI: $115 – $280) per vaccinated recipient.
Conclusions: For the five-season period of 2010/11 through 2014/15, HD influenza vaccination was asso-
ciated with net cost savings due to fewer hospitalizations, and therefore lower direct medical costs, for
cardio-respiratory disease as compared to SD influenza vaccination in the senior US VHA population.
 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Adults 65 years and older (hereinafter referred to as seniors) are
at an increased risk for complications caused or triggered by an
influenza infection [1]. Young-Xu and colleagues estimated the
range of annual direct medical costs of influenza-attributablehospitalizations at Department of Veterans Affairs (VA) Medical
Centers for senior Veterans Health Administration (VHA) enrollees
over five respiratory seasons (2010/11 through 2014/15) to be
between 24 and 34 million US dollars [2]. Given this substantial
cost, a health economic analysis of the various influenza vaccina-
tion strategies for this age group is pertinent.
One of the vaccination options available to the VHA during this
period was the injectable high-dose inactivated trivalent influenza
vaccine (Fluzone High-Dose, Sanofi Pasteur, PA, US, licensed in the
US in 2009 for people aged 65 years and older; hereinafter referred
4500 R. van Aalst et al. / Vaccine 37 (2019) 4499–4503to as the high-dose vaccine (HD)). HD contains four times more
influenza hemagglutinin antigen than standard-dose trivalent
influenza (SD) vaccines (60 lg vs. 15 lg per strain), improving
immune response and therefore protection, in seniors. Young-Xu
et al. [3] reported a relative vaccine effectiveness (rVE), or addi-
tional reduction, of HD versus SD of 10% (95% CI, 8% –12%) for
all-cause hospitalization; 18% (95% CI, 15%–21%) for cardio-
respiratory-associated hospitalization; and 14% (95% CI, 6% –22%)
for influenza/pneumonia-associated hospitalizations during five
respiratory seasons (2010/11 through 2014/15).
Various features of the Young-Xu et al. (2019) study enable us
to assess the contribution of HD in lowering the direct medical cost
of influenza-attributable hospitalizations, thereby improving the
accuracy of economic burden estimations. First, the study included
hospitalizations in non-VA medical centers. The majority of senior
Veterans are ‘‘dual users” and receive care in both VA and non-VA
facilities paid for by Medicare [4,5]. Second, the study captured five
rather than one single respiratory season. Incorporating seasonal
variation in influenza viral circulation and vaccine effectiveness
increases the confidence in our economic assessment as an average
economic effect. Third, the study used a statistical method to
adjust for observable and unobservable differences between the
HD and SD recipients.
In this paper, we will assess the economic impact of HD versus
SD vaccination on cost of hospitalization for cardio-respiratory dis-
ease in the population analyzed by Young-Xu et al. (2019). In addi-
tion, we estimate the economic impact in a scenario where 10% of
the study population had received HD and 90% SD.2. Methods
2.1. Study Design, population and data sources
The Young-Xu et al. [3] study, a retrospective cohort study with
approximately 700,000 patients included in each of the five respi-
ratory seasons, compared hospitalizations between those who
received HD versus SD at a VA facility. Patients were included
when they were at least 65 years old at vaccination, had received
only one HD or SD vaccine in the seasons of interest, and had
sought medical care at a VA facility in the six months before vacci-
nation. This resulted in a study population of 3.5 million SD and
158,636 HD person-seasons. We used the same population and
methods of Young-Xu et al. (2019) to calculate rVEs for the present
study. In summary, for each study participant at each season, the
baseline period (during which baseline characteristics were mea-
sured) was defined from the beginning of each respiratory season
in week 27 (beginning of July) until his or her influenza vaccination
date. The observation period (during which study outcomes were
measured) was defined from two weeks after vaccination until
the end of the respiratory season in week 26 (end of June). Crude
rVE rates were adjusted for treatment selection bias (confounding
by indication) using differences in observable baseline characteris-
tics between the cohorts that included demographics, comorbidi-
ties adapted from the Deyo-Charlson comorbidity score [6], and
VA priority group, a surrogate measure for socio-economic status
(Appendix 1) [7]. In addition, an instrumental variable (IV) based
on the facility’s treatment preference for HD, defined as the pro-
portion of HD recipients at a certain facility in a given respiratory
season, was used to act as a pseudo-randomizer of unobservable
differences [3].
VHA is the largest integrated health care system in the US, pro-
viding care at 1,240 health care facilities, including 170 VA Medical
Centers and 1,061 outpatient sites of care of varying complexity
(VA outpatient clinics) to over nine million Veterans enrolled in
healthcare through VA [8]. Admissions to VA hospitals werederived from its unified electronic medical record system (EMR)
that contains information about inpatient, outpatient, and emer-
gency department (ED) visits.
For the cost of vaccination in VA facilities, we obtained data
from the National Acquisition Center Contract Catalog Search Tool
[9]. Hospitalizations, and their reimbursement costs, of VHA enrol-
lees that occurred in non-VA facilities were obtained from the
Centers for Medicare and Medicaid Services (CMS) administrative
fee-for-service claims. These records supplement those in the
VHA database as many patients seek healthcare outside VA once
eligible for CMS benefits. While VHA applies a system of cost allo-
cation, costs of non-VA hospitalizations are based on insurance
reimbursements, which do not necessary reflect true costs for the
healthcare provider [10].
The study received institutional review board approval from the
Veteran’s Institutional Review Board of Northern New England at
the White River Junction VA Medical Center.
2.2. Outcomes and IV-adjusted rVEs
Our primary outcome of interest was an acute hospitalization
for cardio-respiratory disease, defined by its principal discharge
diagnosis (International Classification of Diseases, Ninth Revision,
ICD-9: 390-519, Appendix 2). Because this definition is less inclu-
sive than the definition by Young-Xu et al. (2019) that included
both acute hospitalizations and nursing home admissions, we
recalculated rVEs using the same statistical model for cardio-
respiratory disease. We assessed HD’s impact on cost of acute hos-
pitalization for pneumonia or influenza (P&I) as well. Because
expected underreporting of these hospitalizations introduced sig-
nificant bias in the estimation of incidence rates, we refer for the
results to Appendices 3 and 4 [11–13]. In addition, we report
HD’s impact on a more sensitive outcome, all-cause hospitaliza-
tions, in these appendices.
2.3. Economic assessment
The need to adjust the crude rVE for treatment selection bias
prevented us from a straight comparison of costs incurred by the
HD recipients to those incurred by the SD recipients. We used a
model based on the incidence rate ratio (RR) derived from the
IV-adjusted rVE (1) and applied the RR to the total number of out-
comes YTð Þ, adjusted for number of HD and SD recipients (NHD and
NSD, respectively), to estimate the number of outcomes in the SD
cohort (2).
rVE ¼ 1 RRð Þ  100%;RR ¼ YHD=NHD
YSD=NSD
ð1Þ







WhereNT is the study population size in a given respiratory season
and consisting of all vaccine recipients (NT ¼ NHD þ NSDÞ; YT is the
total number of observed outcomes (e.g. hospitalizations for
cardio-respiratory disease) in the study population; bYSDand bYHD
are the number of outcomes attributed to the SD and HD recipients
YT ¼ bYSD þ bYHD ; RR is the IV-adjusted incidence rate ratio; and
HospitalizationrateSDis the hospitalization rate of outcome bYSD in
the group of SD recipients.
After adjusting the observed outcomes with the season and
outcome-specific rVE, we calculated the absolute risk reduction
Table 1
Number of influenza vaccinations, hospitalization rates for cardio-respiratory disease,
and number needed to treat (NNT) to prevent one hospitalization for VHA enrollees
vaccinated during respiratory seasons 2010–11 through 2014–15.
Study cohort 3,638,924
HD recipients 158,636 4.4%
SD recipients 3,480,288 95.6%
Observed hospitalizations 478,982
Applied rVE 14% (8–19%)
Hospitalization incidence rates
Rate HD recipients 0.114 (0.108–0.121)
Rate SD recipients 0.132 (0.132–0.133)
Treatment effect
Number Needed to Treat 55 (40–93)
R. van Aalst et al. / Vaccine 37 (2019) 4499–4503 4501[ARR] by subtracting the incidence rate in the HD cohort from the
SD cohort. The multiplicative inverse of ARR results in the number
needed to treat (NNT = 1/ARR): the number of patients that need to
be switched over from SD to HD to prevent one hospitalization. For
cost of vaccination, we averaged season specific vaccine and
administration costs. To increase the accuracy of the economic
assessment and reduce the impact of data entry errors and rare-
but-extreme values, we removed the top and bottom two per-
centiles equivalent to at least two standard deviations in a normal
distribution of the observed hospitalization costs, as was done by
Young-Xu et al. (2017), retaining 96% of observations in the cost-
analysis [2,14]. Because variation in vaccination cost was small,
we included all observations. We used random sampling with
replacement bootstrapping to calculate 95% confidence intervals
(CI).
To evaluate cost-savings of HD vaccination, we estimated the
difference in costs per SD recipient as if they had received HD
instead. This was calculated as the average cost of a hospitalization
for an SD recipient divided by the number needed to treat (NNT)
minus the average cost difference of administering the two vac-
cines. The cost of administering a vaccine included the cost of
the vaccine itself as well as the cost of the administration process
(vaccine injection and record keeping). We calculated the total
realized cost-savings by multiplying the total number of HD recip-
ients by the cost-savings per patient. The maximum (potential)
savings were calculated by dividing the total savings by the HD
proportion minus the number of HD recipients divided by the















Where YSDis the number of observed outcomes in the SD cohort,
CostYSD are the total costs of these outcomes, NHD the number of
HD recipients, CostHD the total cost of vaccinating the HD cohort,
NSD the number of SD recipients, and CostSD the total cost of vacci-
nating the SD cohort. SavingsSD!HD are the estimated savings per
SD recipient if they had received an HD vaccination instead.
The lower limit of the CI for cost-savings is based on the lower
limit of the CI for the rVE, the upper limit for incremental costs of
vaccination, and the lower limit of hospitalization costs. We
applied the opposite limits of the ones used to calculate the lower
limit for the upper limit. The variation in VHA costs and Medicare
reimbursements, as well as variation in the cost of vaccination, are
reflected in their CI.
We first calculated season-specific NNTs and cost-savings using
season-specific numbers of HD and SD recipients, observed hospi-
talizations and costs, for which the results are presented in Appen-
dices 3 and 4. We then analyzed combined data from all five
seasons longitudinally, accounting for repeated measures from
patients appearing in multiple seasons, to provide one summary
measure of NNT and cost-savings.
2.4. Sensitivity analysis
We performed three sensitivity analyses to test the robustness
of our findings. First, our economic assessment reassigns the
observed total number of outcomes to the HD and SD cohorts using
the IV-adjusted rVE. We assume that the true proportion of out-
comes in VHA-hospitals does not change after this reassignment.
To explore the sensitivity of the cost-savings to potential changes
of the true proportion, we varied the observed proportion of
hospitalizations with underlying cardio-respiratory disease by 25
percentage points in either direction. This allowed us to model abest/worst case scenario without negative hospitalizations in any
of the five respiratory seasons (Appendix 6). Second, we report a
historical cost-assessment that will change if underlying costs
change. To explore the sensitivity of the historical cost savings to
changes in the incremental cost of vaccination – the average cost
difference of administering the two vaccines – we explored a sce-
nario in which the incremental cost of vaccination is doubled,
aligning it more closely to the values of $19.75 and $20.00 reported
in other studies, with and without a 5 percentage point increase of
the cost of hospitalization (Appendix 7) [15–17]. We recognize that
VHA cost and CMS reimbursement are imperfect proxies of the true
cost of a hospitalization. The VHA system of cost-allocation may
allow for cost inefficiency, whereas CMS reimbursements do not
always cover true costs incurred by a facility or healthcare provider
[10,18]. In other words, VHA cost may be an overestimation of true
cost, while the CMS reimbursements may be an underestimation.
We therefore performed a sensitivity analysis in which VHA costs
were reduced by 10 and 20 percentage points, while increasing
CMS reimbursement were increased by 10 and 20 percentage
points (Appendices 8 and 9). Last, we explored the effect of
removal of outliers on our results. We repeated the main analysis
including all cost data (Appendix 10).3. Results
During the five-year study period, we analyzed 3.6 million
person-seasons (Table 1). The overall HD proportion has more than
doubled from 3.1% in 2010–11 to 7.7% in 2014–15 (Appendix 2).
We observed 478,982 hospitalizations for cardio-respiratory dis-
ease in our study cohort. We estimated the rVE (HD vs SD) for
acute hospitalizations with underlying cardio-respiratory disease
to be 14% (95% CI: 8%  19%). IV-adjusted hospitalization rates
(outcomes per person-year) were 0.132 (95% CI: 0.132–0.133) for
SD recipients and 0.114 (95% CI: 0.108–0.121) for HD recipients.
Based on these rates, we calculated a number needed to treat
(NNT) of 55 (95% CI: 40–93) to prevent one hospitalization for
cardio-respiratory disease.
The average cost of a VA hospitalization for cardio-respiratory
disease for SD recipients was $16,220 (95% CI: $16,009–$16,430,
Table 2). Average CMS reimbursement to a non-VA facility was
$9,716 (95% CI: $9,652–$9,781) per hospitalization. Of all observed
hospitalizations for cardio-respiratory disease, 32% were seen in a
VA facility, while 68% were observed in a non-VA facility. Average
costs of an HD and SD vaccination were $23.48 (95% CI: $21.29–$
25.85) and $12.21 (95% CI: $11.49–$13.00) per vaccinated patient,
respectively.
We estimated the savings per HD-vaccinated VHA patient to be
$202 (95% CI: $115–$280, Table 3). Estimated total savings were
Table 2
Mean cost and reimbursement per hospitalization for cardio-respiratory disease and
vaccination among vaccinated VHA enrollees during the 2010–11 through 2014–15
respiratory seasons in US dollars.
Hospitalization Mean (95% CI) Weight Value
SD recipients




Vaccination Mean (95% CI)
VHA cost Incremental cost
HD recipients 23.48 (21.29–25.85) 11.27 (9.81–12.86)
SD recipients 12.21 (11.49–13.00)
Table 3
Estimation of realized and potential savings for hospitalizations among vaccinated
VHA enrollees for cardio-respiratory disease in US dollars).
95% CI
Savings Mean (USD) Lower Upper
Per patient SD!HD 202 115 280
Total 32M 18M 44M
Potential 73M 42M 102M
4502 R. van Aalst et al. / Vaccine 37 (2019) 4499–4503$202  158,636 HD recipients = $32 million (95% CI: $18–$44
million) based on an HD proportion of 4.4%. Estimated potential
savings under the assumption that 10% of the study population
had received HD are $202  363,892 HD recipients = $74 million
(95% CI: $42–$102 million). HD remained cost-saving in all sensi-
tivity analyses performed for hospitalizations with underlying
cardio-respiratory disease.4. Discussion
We compared the cost of influenza vaccination and acute hospi-
talization for cardio-respiratory disease of 158,636 HD and 3.6 mil-
lion SD recipients during five respiratory seasons and found that
HD vaccination resulted in average savings of $202 (95% CI:
$115–$280) per recipient. These savings were achieved by a
reduced number of hospitalizations based on HD’s IV-adjusted
rVE of 14% (95% CI: 8%  19%) for cardio-respiratory disease-
associated acute hospitalizations.
Our outcome definitions were less inclusive than the definitions
used by Young-Xu et al. (2019) that included both acute hospital-
izations and nursing home admissions. Limiting the outcome defi-
nition as such allowed for a more precise comparison of the
observed mean cost of a hospitalization with external sources
and reduced likelihood of overestimation. We estimated the rVE
for acute hospitalizations with underlying cardio-respiratory dis-
ease to be 14% (95% CI: 8%  19%), about 22% lower than the 18%
(95% CI, 15%–21%) estimated by Young-Xu and colleagues for the
same study cohort [3].
Although we estimated substantial savings of $32 million (95%
CI: $18–$44 million) over a five-year period, we feel confident
these are not an overestimation of the true savings for several rea-
sons. First, we did not consider outpatient visits, nursing home
admissions, lost income because of illness, or reductions in quality
of life. Second, the rVE we applied was recalculated for the out-
come of interest: acute hospitalizations with underlying cardio-
respiratory disease. Moreover, the rVE we used is consistent with
ameta-analysis of existing studies of the rVE of HD vs. SD, showing
a 10.4% (95% CI, 1.6% –18.5%) additional reduction of all-cause
hospitalizations and a 27.3% (95% CI, 15.3%–37.6%) additionalreduction of pneumonia-associated hospitalizations [19]. Last,
the average Medicare reimbursements of $9,716 we observed
(Appendix 3, season 2012/13) are in the range reported by Moore
et al. ($8,500–$22,500) for 2012 [20].
VHA funding is appropriated by Congress as a global budget and
distributed to its 23 Veterans Integrated Service Networks (VISNs)
via a form of (risk-adjusted) capitation such that, in general, a VA
hospital does not receive additional money for an additional hospi-
talization. VHA’s electronic Managerial Cost Accounting system
captures the cost of healthcare services, which are not based on
insurance claims, reimbursements or billing data; rather, they are
the aggregate of actual expenses (e.g. salaries, equipment, build-
ings, energy, negotiated drug prices, materials) attributed to a
specific healthcare encounter. Although an additional hospitaliza-
tion in a VA hospital does not result in an immediate additional
cost – due to the capitated payment model – to those ultimately
responsible for the costs, US taxpayers, we believe that the allo-
cated expenses should be considered as opportunity costs: all
resources needed to care for a potentially vaccine-preventable hos-
pitalization could have been used for another admission.
Because our objective is not to compare cost of care between VA
and non-VA facilities, but to estimate cost to the US taxpayer, we
consider differences in VHA costs and Medicare reimbursement
data to be acceptable.
Our cost-saving estimate of $202 per patient is between the net
savings of $91 Chit and colleagues calculated in a randomized con-
trolled trial (RCT) for cardio-respiratory hospitalizations, and the
$262 per patient Shireman et al. estimated for acute hospitaliza-
tions in the US nursing home population [15,16]. RCT participants
were drawn from the general, relatively healthy population. The
Veteran patient population, in contrast, is on average older, pre-
dominantly male, has a higher prevalence of comorbid conditions
and poorer health status than the general population [21]. If
patients with a poorer health status benefit more from HD than
healthy patients, it is logical that the estimated savings found in
our study are closer to the savings observed for nursing home res-
idents than to those in the general population.
Strengths and limitations of the study cohort and the statistical
method of IV estimation we used in our calculations have been
reported elsewhere [3]. Additional strengths include the size and
longitudinal observation of the cohort over multiple seasons. Sea-
sonal variation in influenza viral activity and vaccine efficacy
caused by a better or worse match between circulating strains
and those included in the vaccine portends seasonal variation in
the severity of influenza; therefore, incorporating multiple seasons
in this analysis increases confidence in our assessment as an aver-
age economic effect. During the span of our study we observed two
seasons with a high severity (2012/13 and 2014/15), two with
moderate (2010/11 and 2013/14), and one with a low (2011/12)
severity [22]. The predominant circulating strain in the two high
severity seasons was H3N2, while 2012/13 saw additional B strain
circulation. As the Food and Drug Administration decides which
strains must be included in vaccines sold in the US, the HD and
SD vaccines contain similar strains in a given season. In the
2012/13 seasons, the vaccines were a good match with the circu-
lating strains, while the vaccines in 2014/15 were not well
matched [23]. Notably, HD rVEs and costs did not significantly vary
over the course of the five seasons, resulting in relatively consis-
tent savings.
In addition, IV estimation can adjust for selection bias caused by
preferential treatment based on patient characteristics that are not
visible to researchers. An example of a patient characteristic that is
visible to a VA health care provider, but not captured in our data
set is ‘‘frailty”. However, in order to adequately adjust for unmea-
sured confounders, IV estimation requires an instrument that sat-
isfies the underlying assumptions of the method. Only then does
R. van Aalst et al. / Vaccine 37 (2019) 4499–4503 4503the instrument works as a randomizer. An important assumption –
that the instrument is not associated with the outcome – can never
be entirely ruled out. Our instrument, a facility’s treatment prefer-
ence for HD, targets patients who would have received a different
vaccine if they had gone to a different VA facility. It is impossible to
identify these ‘‘marginal patients” in the study population.
The value of a prevented hospitalization is the weighted aver-
age of the cost of a VA hospitalization and the reimbursement of
a non-VA hospitalization. The weights were based on the propor-
tion of observed hospitalizations in VA and non-VA facilities.
Because VHA costs are almost twice the value of Medicare reim-
bursements, this proportion has a big impact on the value of a pre-
vented hospitalization. We used the observed proportion to
estimate savings under the assumption that HD prevents the same
percentage of hospitalizations in VA and non-VA facilities. We can-
not verify this assumption with our current data set. However, HD
remained cost saving in the sensitivity analysis for which the
observed proportion was altered by 25 percentage points in either
direction (Appendix 6).
Furthermore, we did not include costs of healthcare utilization
associated with vaccine side effects. Safety data from the RCT
showed increased rates of local reactogenicity observed in HD
recipients; however, injection site symptoms were generally not
severe and resolved quickly, and overall rates of systemic com-
plaints were comparable to those of the SD recipients [24].
Our study population is not representative of the general VHA-
enrolled population: we included patients who had sought medical
care at a VA facility in the six months before vaccination, which
excluded approximately 30% of enrollees who received an HD or
SD vaccine in a VA facility.
5. Conclusion
We estimate that offering the HD vaccine instead of SD to this
Veteran study population has saved the US taxpayer $32 million
(95% CI: $18 - $44 million) over a five-year period as a result of
fewer hospitalizations due to underlying cardio-respiratory dis-
ease. Although we believe that switching more senior patients
from SD to HD will result in higher total net savings – our findings
show a 5.6% increase in vaccination coverage can result in savings
of $73 million (95% CI: $42 - $104 million) – additional analysis is
necessary to confirm this hypothesis.
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